Extract
Nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD), an intriguing and incompletely understood condition, is characterised by a triad of asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) and hypersensitivity to aspirin (acetylsalicylic acid; ASA) and other cyclooxygenase-1 inhibiting NSAIDs [1, 2]. Dysregulation of arachidonic acid metabolism leads to chronic overproduction of the cysteinyl leukotrienes and the inflammatory prostaglandin (PG) D2 along with underproduction of anti-inflammatory PGE2; these are further increased acutely on exposure to NSAIDs [1, 2]. Intense T2 eosinophilic inflammation, involving both CRSwNP and asthma, precede the onset of clinical NSAID sensitivity and persist in the absence of NSAID exposure [1].
Abstract
Schneider et al. add to the growing evidence that dupilumab is very effective in N-ERD inducing increased tolerance to ASA in 57% of patients (complete in 23%), accompanied by improvements in both upper and lower airway clinical features of disease https://bit.ly/3jqs1DC
Acknowledgement
The author thanks Jacquie Bramley for assistance in preparing ths manuscript.
Footnotes
Conflict of interest: In the past 36 months, D.W. Cockcroft has received research grants from the University of Saskatchewan, AstraZeneca Canada and Biohaven Pharmaceuticals, all unrelated to the current paper.
- Received December 22, 2022.
- Accepted January 27, 2023.
- Copyright ©The authors 2023. For reproduction rights and permissions contact permissions{at}ersnet.org
LIBRARY USERS
Log in through your institution
Purchase access
